From the Journals

Breast Cancer

I-SPY2.2: RT-DXd May Reduce Chemotherapy Exposure in Immune-Positive Early Breast Cancer

November 17 3 min read
Neoadjuvant treatment with the immune-directed bispecific antibody rilvegostomig plus the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (RT-DXd) demonstrated “promising” activity with mostly low-grade adverse events in patients with immune-positive, ERBB2-negative early breast cancer, according to findings from the adaptively randomized, multicenter phase II I-SPY2.2 platform trial.

Latest in From the Journals